Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China Healthwise HoldingsHKSE:00348 +2.99% 3-Year ROIIC % is 0.85 as of Dec. 2025. The stock has 3 warning signs investors should review. Among 617 Healthcare Providers & Services companies, China Healthwise Holdings ranks worse than 54.46% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
China Healthwise Holdings's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 0.85%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for China Healthwise Holdings's 3-Year ROIIC % or its related term are showing as below:
HKSE:00348's 3-Year ROIIC % is ranked worse than 54.46% of 617
companies
in the Healthcare Providers & Services industry
Industry Median: 3.66
vs HKSE:00348: 0.85
China Healthwise Holdings (HKSE:00348) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
China Healthwise Holdings 3-Year ROIIC % Related Terms
China Healthwise Holdings 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Healthwise Holdings 3-Year ROIIC % Competitor Comparison
For the Pharmaceutical Retailers subindustry, China Healthwise Holdings's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Healthwise Holdings 3-Year ROIIC % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, China Healthwise Holdings's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where China Healthwise Holdings's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
China Healthwise Holdings (HKSE:00348) has a 3-Year ROIIC % of 0.85 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on China Healthwise Holdings and its competitors. According to the industry distribution chart, China Healthwise Holdings ranks #336 out of 617 companies in the Healthcare Providers & Services industry, placing it in the top 54.5%.
Is China Healthwise Holdings' 3-Year ROIIC % too high?
China Healthwise Holdings' current 3-Year ROIIC % is 0.85. The Healthcare Providers & Services industry median 3-Year ROIIC % is 3.66. China Healthwise Holdings' value of 0.85 is 76.8% below this industry median. Based on the distribution chart, China Healthwise Holdings ranks #336 out of 617 companies in the Healthcare Providers & Services industry, which is below the industry midpoint.
How does China Healthwise Holdings' 3-Year ROIIC % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, China Healthwise Holdings ranks #336 out of 617 companies for 3-Year ROIIC %. This places China Healthwise Holdings in the lower half of its industry. The industry median 3-Year ROIIC % is 3.66. China Healthwise Holdings' value of 0.85 is 76.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Healthcare Providers & Services company?
The median 3-Year ROIIC % among Healthcare Providers & Services companies is 3.66, based on 617 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Healthwise Holdings's current 3-Year ROIIC % of 0.85 is 76.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on China Healthwise Holdings and its competitors. For the Healthcare Providers & Services industry, the median 3-Year ROIIC % is 3.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Healthwise Holdings's current 3-Year ROIIC % is 0.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Healthwise Holdings stock overvalued right now?
Based on GuruFocus' analysis, China Healthwise Holdings (HKSE:00348) is currently considered Modestly Overvalued. The stock's GF Value™ is HK$0.06, compared to a current price of HK$0.07 — trading 15% above its estimated fair value. The current 3-Year ROIIC % is 0.85 and 76.8% below the Healthcare Providers & Services industry median of 3.66. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For China Healthwise Holdings (HKSE:00348), the current 3-Year ROIIC % is 0.85 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
China Healthwise Holdings Ltd is an investment holding company. It operates in three segments: Chinese health products, Money lending business, and investment in financial instruments. The majority of its revenue comes from trading in Chinese health products, which includes, pharmaceutical products, ginseng, and dried seafood products. The company's geographical segments are Hong Kong and the PRC, of which key revenue is derived from Hong Kong.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00348 has been successfully added to your 
